Electromed (ELMD) Stock Price, News & Analysis

Company Overview

Electromed, Inc. is a medical technology company specializing in the development, manufacturing and distribution of respiratory support and diagnostic systems. The company’s flagship offering, the The Vest® Airway Clearance System, employs High Frequency Chest Wall Oscillation (HFCWO) therapy to assist patients in clearing mucus from their lungs. In addition to its core respiratory care products, Electromed provides a suite of diagnostic monitoring and biofeedback devices designed to complement its therapeutic portfolio and support clinicians in optimizing patient outcomes.

Founded in 1990 and headquartered in Cleveland, Ohio, Electromed has grown from a single-product enterprise to a diversified medical device manufacturer. Over the decades, the company has expanded its product pipeline through both in-house research and strategic collaborations with academic institutions and clinical centers. Electromed’s manufacturing operations adhere to rigorous quality standards, including FDA and ISO certifications, ensuring that its devices meet stringent safety and efficacy requirements.

Electromed’s market presence spans North America, Europe and select Asia-Pacific regions. The company leverages a combination of direct sales teams, contracted distributors and strategic partnerships to serve hospitals, outpatient clinics and home healthcare providers. By tailoring its sales and marketing initiatives to regional regulatory landscapes and reimbursement environments, Electromed aims to facilitate broader patient access to its respiratory care solutions.

Guided by an experienced management team with deep expertise in medical device innovation, regulatory affairs and reimbursement strategy, Electromed continues to invest in research and development. The company’s leadership emphasizes collaboration with healthcare professionals and patient advocacy groups to refine existing technologies and explore new applications for airway clearance therapy. Electromed remains committed to advancing respiratory health through ongoing product enhancements and a focus on evidence-based care.

Key Stats

• Today's Range: $20.12 to $20.83
• 50-Day Range: $19.34 to $23.22
• 52-Week Range: $13.74 to $35.56
• Volume: 75,091 shs
• Average Volume: 80,103 shs
• Market Capitalization: $174.26 million
• P/E Ratio: 27.71
• Dividend Yield: N/A
• Price Target: $38.00
• Consensus Rating: Strong Buy

Electromed Stock Analysis - MarketRank™

Electromed scored higher than 24% of companies evaluated by MarketBeat, and ranked 817th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Electromed has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Electromed is 27.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Electromed is 27.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.65.

Price to Book Value per Share Ratio

Electromed has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.26% of the float of Electromed has been sold short.

Short Interest Ratio / Days to Cover

Electromed has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electromed has recently decreased by 9.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Electromed does not currently pay a dividend.

Dividend Growth

Electromed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.26% of the float of Electromed has been sold short.

Short Interest Ratio / Days to Cover

Electromed has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electromed has recently decreased by 9.10%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Electromed this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ELMD on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

MarketBeat Follows

5 people have added Electromed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Electromed insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.00% of the stock of Electromed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.82% of the stock of Electromed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELMD Stock Analysis - Frequently Asked Questions

How have ELMD shares performed this year?

Electromed's stock was trading at $29.55 at the beginning of 2025. Since then, ELMD stock has decreased by 29.7% and is now trading at $20.78.

How were Electromed's earnings last quarter?

Electromed, Inc. (NYSE:ELMD) issued its quarterly earnings data on Tuesday, November, 12th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.13. The firm had revenue of $14.67 million for the quarter. Electromed had a net margin of 11.34% and a trailing twelve-month return on equity of 15.71%.

How will Electromed's stock buyback program work?

Electromed's board authorized a share repurchase program on Monday, March 10th 2025, which allows the company to buy back $5,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

How do I buy shares of Electromed?

Shares of ELMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Electromed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Electromed investors own include NVIDIA (NVDA), Enterprise Products Partners (EPD), Energy Transfer (ET), Meta Platforms (META), Pfizer (PFE), TransEnterix (TRXDW) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/06/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ELMD
• CIK: 1488917
• Web: smartvest.com
• Phone: (952) 758-9299
• Fax: 866-758-5077
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $38.00
• High Stock Price Target: $38.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +82.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 4.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.79
• Trailing P/E Ratio: 27.71
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.15 million
• Net Margins: 11.34%
• Pretax Margin: 15.57%
• Return on Equity: 15.71%
• Return on Assets: 13.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.10
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $61.44 million
• Price / Sales: 2.84
• Cash Flow: $0.50 per share
• Price / Cash Flow: 41.36
• Book Value: $5.10 per share
• Price / Book: 4.07

Miscellaneous

• Outstanding Shares: 8,386,000
• Free Float: 7,359,000
• Market Cap: $174.26 million
• Optionable: Optionable
• Beta: 0.41